HC Wainwright & Co. Initiates Coverage On Ascendis Pharma with Buy Rating, Announces Price Target of $345

Ascendis Pharma A/S

Ascendis Pharma A/S

ASND

0.00

HC Wainwright & Co. analyst Mitchell S. Kapoor initiates coverage on Ascendis Pharma (NASDAQ: ASND) with a Buy rating and announces Price Target of $345.